People s United Financial Inc. raised its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 110,093 shares of the medical research company’s stock after purchasing an additional 3,211 shares during the quarter. People s United Financial Inc.’s holdings in Amgen were worth $18,961,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of AMGN. RNC Capital Management LLC raised its position in shares of Amgen by 10.0% during the first quarter. RNC Capital Management LLC now owns 129,993 shares of the medical research company’s stock valued at $21,328,000 after buying an additional 11,822 shares during the last quarter. Meadow Creek Investment Management LLC raised its position in shares of Amgen by 22.4% during the first quarter. Meadow Creek Investment Management LLC now owns 25,200 shares of the medical research company’s stock valued at $4,135,000 after buying an additional 4,608 shares during the last quarter. Affinity Investment Advisors LLC raised its position in shares of Amgen by 1.0% during the first quarter. Affinity Investment Advisors LLC now owns 86,970 shares of the medical research company’s stock valued at $14,269,000 after buying an additional 884 shares during the last quarter. Main Street Research LLC raised its position in shares of Amgen by 1.0% during the first quarter. Main Street Research LLC now owns 68,468 shares of the medical research company’s stock valued at $11,233,000 after buying an additional 692 shares during the last quarter. Finally, Morningstar Investment Services LLC raised its position in shares of Amgen by 283.8% during the first quarter. Morningstar Investment Services LLC now owns 497,503 shares of the medical research company’s stock valued at $81,625,000 after buying an additional 367,894 shares during the last quarter. 78.38% of the stock is currently owned by institutional investors and hedge funds.

Shares of Amgen, Inc. (AMGN) opened at $175.41 on Monday. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72. Amgen, Inc. has a 1 year low of $141.00 and a 1 year high of $191.10. The firm has a market cap of $127,330.00, a price-to-earnings ratio of 13.94, a P/E/G ratio of 2.54 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. During the same quarter in the previous year, the business posted $3.02 earnings per share. The business’s revenue was down .7% compared to the same quarter last year. analysts forecast that Amgen, Inc. will post 12.66 EPS for the current fiscal year.

Amgen declared that its board has authorized a share buyback plan on Wednesday, October 25th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 8th. Shareholders of record on Friday, November 17th were given a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.62%. The ex-dividend date was Thursday, November 16th. Amgen’s dividend payout ratio (DPR) is 41.55%.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Insiders have sold 7,050 shares of company stock worth $1,239,673 in the last quarter. Company insiders own 0.19% of the company’s stock.

AMGN has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $199.00 price objective on the stock in a research report on Friday, October 27th. Bank of America lifted their price objective on shares of Amgen to $210.00 and gave the company a “buy” rating in a research report on Thursday, October 5th. Barclays lifted their price objective on shares of Amgen from $180.00 to $190.00 and gave the company an “equal weight” rating in a research report on Friday, October 13th. Oppenheimer reiterated a “buy” rating and set a $203.00 price objective on shares of Amgen in a research report on Thursday, September 7th. Finally, Royal Bank Of Canada began coverage on shares of Amgen in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price target on the stock. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $190.22.

COPYRIGHT VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/11/people-s-united-financial-inc-has-18-96-million-holdings-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.